text: Yo, check it out, here's the lowdown,
  Advanced cancers, we see 'em goin' to town,
  Therapeutics be bringin' that dramatic response,
  But minimal residual disease, yo, it's the con,
  Patients relapsin', we need to understand,
  The biology of MRD, it's a demand.
  
  Single-cell RNA sequencing, that's the key,
  Isolatin' malignant cells, let's see what we see,
  BRAF mutant melanoma, we got the scoop,
  Xenograft cohorts, RAF/MEK-inhibition loop,
  Transcriptional states, drug tolerance in play,
  MRDs and biopsies, on treatment they stay,
  Different combos of states, that's the deal,
  Co-occur in MRDs, it's the real deal.
  
  One state stands out, it's got the shine,
  Neural crest stem cell program, it's prime,
  Drivin' by RXRG, the nuclear receptor,
  It's the main player, the disease defector,
  But hold up, we got a trick up our sleeve,
  An RXR antagonist, the NCSCs we deceive,
  Stops 'em from accumulatin' in MRD,
  Resistance delayed, that's the guarantee.
  
  NCSCs, they be the drivers of resistance,
  MRD-directed therapy, our persistence,
  We see the potential, we see the way,
  To tackle the heterogeneity, keep it at bay,
  Gene regulatory networks, we reprogram,
  Therapeutic exploitation, like a bomb,
  Limitin' cellular heterogeneity, that's the goal,
  Fightin' disease progression, therapy resistance we control.